Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
48.9M
-
Shares change
-
+7.16M
-
Total reported value, excl. options
-
$2.49B
-
Value change
-
+$367M
-
Put/Call ratio
-
9.48
-
Number of buys
-
93
-
Number of sells
-
-55
-
Price
-
$50.99
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2018
188 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.9M shares
of 96M outstanding shares and own 50.96% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.26M shares), Capital Research Global Investors (5.91M shares), BlackRock Inc. (4.23M shares), VANGUARD GROUP INC (3.95M shares), FMR LLC (3.94M shares), Capital International Investors (3.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.25M shares), STATE STREET CORP (2.02M shares), FEDERATED INVESTORS INC /PA/ (1.2M shares), and AMERIPRISE FINANCIAL INC (1.2M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.